



March 11, 2024

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1, G - Block
Bandra –Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir(s),

Sub: Intimation about Distribution and Promotion Agreement between AstraZeneca Pharma India Limited ("Company") and Mankind Pharma Limited for innovative budesonide and formoterol fumarate dihydrate (Symbicort)

Please find enclosed the copy of press release in connection with a Distribution and Promotion Agreement entered into by the Company with Mankind Pharma Limited for the distribution of budesonide and formoterol fumarate dihydrate (brand name Symbicort) in India.

Further, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**, in this regard.

Kindly take the above information on record.

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatata, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India

Bangalore, India: March 11 2024 - AstraZeneca Pharma India Limited (AstraZeneca India) (BSE : 506820, NSE : ASTRAZEN) and Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths. It highlights a clear scope of improving the way asthma is managed in the country¹. " Our aspiration is to be pioneers in science and lead in specialist disease areas. We are focused on transforming outcomes for patients and contributing sustainably to people, society and the planet. The partnership with Mankind Pharma presents an opportunity to accelerate access and maximize the potential of our asthma drug as well as the turbuhaler which is a simple device², efficient in consistently delivering a higher proportion of respirable particles than the other devices. As much as we are excited to bring innovative medicine to India fast, we are equally invested on improving access strategically in the country" **said Dr. Sanjeev Panchal, Managing Director and Country President of AstraZeneca India.**

With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas. **Commenting on the agreement with AstraZeneca India, Mr Atish Majumdar, Sr. President – Sales & Marketing, Mankind Pharma Limited said** "Mankind has always been steadfast in providing access to quality treatments to the deserving patients across the nation. In this regard, we are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating Asthma. Symbicort's dual mechanism of action and ease of use in a single inhaler can greatly help patients manage these conditions and improve their quality of life. Through our field forces' extensive outreach, we hope to strengthen access across urban and rural markets. With our shared goal to enable better patient outcomes, I see this collaboration as strategic in more ways than one. We believe such credible partnerships that widen availability of globally established medicines in India exemplify our ethos of putting patients first while ensuring value."

Globally AstraZeneca is an established leader in respiratory care, a disruptor in immunology and will continue to transform care for some of the most debilitating and chronic respiratory and immune-mediated diseases. With an ambition to transform Respiratory & Immunology care for patients in India, moving beyond symptom control to disease modification, remission and, one day, cure, AstraZeneca India is focused to be number 1 in respiratory Biologics.

AstraZeneca is present in therapy areas including Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in India and is focused on transforming the future of healthcare by unlocking the power of what science can do for people, society and planet.

1. Lung India 2022;39:331-6
2. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;
3. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Biopharmaceuticals and Rare Diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: www.astrazeneca.in

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 28 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 600 scientists. For more information, visit www.mankindpharma.com

For media queries please contact:

AstraZeneca Pharma India Ltd

Sindhu Manivannan-9873712924-sindhu.manivannan@astrazeneca.com

Mankind Pharma

Natasha Raj- 9205057627- natasha.raj@mankindpharma.com

Apoorva Sharma- 9999739452- apoorva.sharma@adfactorspr.com

1. Lung India 2022;39:331-6
2. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836-849;
3. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836-849;

Annexure - A

Sl. No.	Particulars	Details
1.	Name of the entity with whom the agreement/ JV is signed	Mankind Pharma Limited
2.	Area of agreement/ JV	Distribution and Promotion
3.	Domestic/International	Domestic
4.	Share exchange ration / JV ratio	NA
5.	Scope of business operation of agreement	Distribution and Promotion
6.	Details of consideration paid / received in agreement / JV	Payment of Rs. 15 crore to be received from Mankind Pharma Limited as per the Distribution and Promotion Agreement
7.	Significant terms and conditions of agreement / JV in brief	Exclusive deal where the Distributor will distribute and promote the product Symbicort for a period of 5 years in the territory of India.
8.	Whether the arrangement is within related party transactions	No
9.	Whether the promoter/promoter group/ group companies have any interest in the entity being acquired	NA
10.	Size of the entity	The revenue from operations of Mankind Pharma Limited on consolidated basis for FY 2022-23 stood at ₹ 8,749.43 crores.
11.	Rationale and benefit expected	Improve access to innovative AstraZeneca medicines in India by leveraging Mankind's strong presence & coverage in respiratory therapy area.